Shuttle Pharmaceuticals Holdings, Inc. — Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. is a discovery- and development-stage pharmaceutical company developing cancer therapies, including Ropidoxuridine for use with radiation therapy and a pipeline of HDAC inhibitors. The company has no commercial revenue and remains focused on research, clinical development, manufacturing, and regulatory preparation.
The filing covers the three and nine months ended September 30, 2023. The condensed consolidated financial statements are unaudited. Common shares outstanding were 15,999,125 as of November 13, 2023.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 in 2023 and 2022 | $0 in 2023 and 2022 |
| Operating expenses | $1.60 million, versus $0.82 million | $4.61 million, versus $1.81 million |
| Net loss | $1.79 million, versus $0.998 million | $4.95 million, versus $2.28 million |
| Net loss per share | $0.11 loss, versus $0.10 loss | $0.34 loss, versus $0.23 loss |
| Cash used in operating activities | Not separately disclosed for the quarter | $4.52 million, versus $2.03 million |
Gross and operating margins are not meaningful because the company generated no revenue. Nine-month research and development expense was $3.08 million, general and administrative expense was $0.45 million, and legal and professional expense was $1.07 million.
Other expense for the nine-month period was $0.34 million, including $1.95 million of interest expense, $0.48 million of loss on convertible-debt settlement, and a $2.12 million non-cash gain from changes in derivative liabilities.
Liquidity, Cash Flow, and Debt
- Cash and cash equivalents were $3.89 million at September 30, 2023, down from $8.42 million at December 31, 2022.
- Marketable securities were $2.92 million at September 30, 2023, compared with none at year-end 2022. Total current assets were $7.00 million and working capital was $6.19 million.
- Cash used in operating activities increased to $4.52 million for the first nine months of 2023 from $2.03 million in the comparable 2022 period.
- Investing activities used $2.92 million, primarily for purchases of marketable securities, compared with no investing cash flow in the prior-year period.
- Financing activities provided $2.90 million, including $3.59 million of net proceeds from the convertible-note and warrant financing, partially offset by repayment of $0.69 million of related-party notes.
- The January 2023 Alto convertible note had $2.59 million of principal outstanding at September 30, 2023, with a net carrying value of $0.60 million after debt discounts. The note matures March 11, 2025, subject to possible extension by the noteholder.
- The Alto note bears stated interest of 5%, but the filing reports an approximately 366% effective interest rate due to discounts, fees, conversion terms, and other features.
- Convertible-note principal and accrued interest were settled through the issuance of 2.38 million common shares during the first nine months of 2023.
- Derivative liabilities were $0.51 million at September 30, 2023 and are classified as Level 3 fair-value measurements.
Material Changes Versus the Prior Comparable Period
- Third-quarter operating expenses increased 95%, driven by higher R&D, general and administrative, and legal and professional costs.
- Nine-month operating expenses increased 154%; R&D rose 194%, primarily because of increased development spending following the 2022 initial public offering and the 2023 convertible financing.
- Nine-month net loss increased 117% to $4.95 million, while loss per share increased to $0.34 from $0.23.
- Operating cash burn more than doubled from the prior-year period, while financing cash inflows declined substantially from the $10.65 million received in the first nine months of 2022.
- Debt-related activity shifted from related-party borrowings to the Alto convertible financing. Related-party principal and accrued interest balances were fully repaid by September 30, 2023.
- Common shares outstanding increased from 13.60 million at December 31, 2022 to 16.00 million at September 30, 2023, primarily due to equity settlements of convertible-note principal and interest.
Outlook, Management Commentary, Risks, and Unusual Items
- Management stated that existing cash, marketable securities, and financing proceeds are expected to fund planned operations through the fourth quarter of 2024. The company has not generated positive operating cash flow and expects substantial additional spending for clinical development, regulatory activities, manufacturing, and potential commercialization.
- Management indicated that Ropidoxuridine API manufacturing, formulation, and packaging activities were completed and that sufficient API was available for the planned Phase II clinical trial.
- The FDA provided positive written responses on September 14, 2023 regarding the company’s proposed Phase II protocol for Ropidoxuridine in patients with unME-MGMT glioblastoma. Management stated that the company remained on track to commence the Phase II study in the fourth quarter of 2023.
- The company retains an option granted to the Alto investor to issue up to an additional $10 million of convertible notes and warrants through December 31, 2025, on substantially similar terms. The filing states that additional capital may be required.
- The Alto financing is highly dilutive and contains variable conversion, acceleration, redemption, make-whole, down-round, and security-interest provisions. The investor has a security interest in the company’s assets and intellectual property until the note is repaid.
- Derivative-liability gains materially reduced reported expense but were non-cash and resulted from valuation changes using Monte Carlo models. Future changes in share price, volatility, and other assumptions could materially affect earnings.
- The company disclosed material weaknesses in internal control over financial reporting related to accounting for significant unusual transactions, the financial-statement close process, and reporting reviews. Management concluded that disclosure controls and procedures were not effective as of September 30, 2023.
- The company reported no pending or threatened legal proceedings believed to be material and no material off-balance-sheet arrangements.
- Subsequent to quarter-end, the company entered into a license agreement with Georgetown University for predictive biomarkers related to adverse effects of radiation therapy. The agreement includes milestone payments and, following commercialization, a guaranteed minimum annual royalty and a 5% royalty on net sales.
Most Important Facts to Verify
- Whether the Phase II Ropidoxuridine trial actually commenced in the fourth quarter of 2023 and its current regulatory and enrollment status.
- The company’s post-quarter-end cash burn, remaining liquidity runway, and whether additional financing has been obtained or is required before the stated fourth-quarter 2024 funding horizon.
- The repayment schedule, conversion activity, effective economic cost, and potential dilution associated with the Alto convertible note and its warrants.
- Whether reported material weaknesses in internal controls have been remediated and whether subsequent filings identify additional accounting corrections.
- The current status, costs, milestones, and royalty obligations under the Georgetown license agreement.
- Whether the company has generated any revenue or secured non-dilutive grants, partnerships, or commercialization arrangements after September 30, 2023.